PS-152 Activin-a: A Biomarker Of Severe Encephalopathy

Autor: NL Denihan, Geraldine B. Boylan, Deirdre M. Murray, AM Looney, Brian H. Walsh
Rok vydání: 2014
Předmět:
Zdroj: Archives of Disease in Childhood. 99:A166.1-A166
ISSN: 1468-2044
0003-9888
DOI: 10.1136/archdischild-2014-307384.448
Popis: Background Hypoxicischaemic encephalopathy (HIE) remains one of the leading causes of neonatal morbidity and mortality. Therapeutic hypothermia may improve the outcome of infants with moderate/severe encephalopathy but only if initiated within six hours of the initial insult. The aim of our study was to determine if umbilical cord blood (UCB) levels of Activin-A, a glycoprotein previously implicated in neuronal brain injury, could identify infants with moderate/severe encephalopathy at birth. Methods Full term infants with perinatal asphyxia (PA) were identified by a cord pH Results In total 156 infants (controls = 78, cases = 78) were included in the study. Cases included 56 infants with PA (non-HIE) and 24 infants with HIE (mild = 14, moderate = 6, severe = 4). Following analysis, a significant increase in Activin-A expression was observed between the control and severe HIE groups, and between the perinatal asphyxia and severe HIE groups (median (SD) = 487.48 (470.21) vs 911.54(594.1) p = 0.032 and 487.95 (384.1) vs 911.54 (594.1), p = 0.035, respectively). No significant difference was seen between PA and mild or moderate HIE. Using a cut-off value of 724.5 pg/ml we report Activin-A has a 100% negative predicitive value, with a sensitivity and specificity of 100% and 70% respectively. Conclusion Our study supports the use of Activin-A as a biomarker of severe encephalopathy.
Databáze: OpenAIRE